Jiaxing TechnoDerma Medicine

TechnoDerma Medicines is a private, clinical-stage dermatology-focused biotech developing novel small-molecule therapies for skin and immune-mediated diseases. The company appears to have originated in Jiaxing, Zhejiang, China and later established operations in Chengdu, with current legal-name references pointing to Tecoro Biotechnology (Chengdu) Co., Ltd. Its lead programs include TDM-105795, a topical thyroid hormone receptor agonist for androgenetic alopecia, and TDM-180935, a topical JAK1/TYK2 inhibitor for atopic dermatitis. Additional pipeline assets include TDM-004 for psoriasis and TDM-003 for systemic lupus erythematosus, plus an earlier-stage skin-scarring collaboration with the University of Michigan. The company has raised multiple private financing rounds including Series A and A+ funding and remains focused on dermatology innovation.